Journal of Biological Chemistry · 2003 · 91 citations · 34 references
MedicineMedicinal ChemistryPharmacologyDrug DesignMolecular PharmacologyStructure-activity RelationshipsAllosteric Drug DesignCellular Drug EffluxDrug-receptor InteractionsLigand BindingTransporter PharmacologyAllosteric DrugsAllosteric PathwaysMechanism Of Allosteric ModulationMultidrug Resistance TransportP-glycoprotein TransportP-glycoprotein Transporter InteractionsP-glycoprotein-mediated EffluxTransporter-mediated Drug Resistance
The human multidrug transporter P-glycoprotein (Pgp, ABCB1) contributes to the poor bioavailability of many anticancer and antimicrobial agents as well as to drug resistance at the cellular level. For rational design of effective Pgp inhibitors, a clear understanding of its mechanism of action and functional regulation is essential. In this study, we demonstrate that inhibition of Pgp-mediated drug transport by cis-(Z)-flupentixol, a thioxanthene derivative, occurs through an allosteric mechanism. Unlike competitive inhibitors, such as cyclosporin A and verapamil, cis-(Z)-flupentixol does not interfere with substrate ([(125)I]iodoarylazidoprazosin) recognition by Pgp, instead it prevents substrate translocation and dissociation, resulting in a stable but reversible Pgp-substrate complex. cis-(Z)-Flupentixol-induced complex formation requires involvement of the Pgp substrate site, because agents that either physically compete (cyclosporin A) for or indirectly occlude (vanadate) the substrate-binding site prevent formation of the complex. Allosteric modulation by cis-(Z)-flupentixol involves a conformational change in Pgp detectable by monoclonal antibody UIC2 binding to a conformation-sensitive external epitope of Pgp. The conformational change observed is distinct from that induced by Pgp substrates or competitive inhibitors. A single amino acid substitution (F983A) in TM12 of Pgp that impairs inhibition by cis-(Z)-flupentixol of Pgp-mediated drug transport also affects stabilization of the Pgp-substrate complex as well as the characteristic conformational change. Taken together, our results describe the molecular mechanism by which the Pgp modulator cis-(Z)-flupentixol allosterically inhibits drug transport.
34
Human P-glycoprotein transports cyclosporin A and FK506.
Takashi Saeki, Kazumitsu Ueda, Yusuke Tanigawara et al. · Journal of Biological Chemistry · 1993 · 685 citations · Full text
Medicine, Biochemistry, Pharmacology +15
Communication between Multiple Drug Binding Sites on P-glycoprotein
Catherine Martin, G. Berridge, Christopher F. Higgins et al. · Molecular Pharmacology · 2000 · 415 citations
Suresh V. Ambudkar, Isabelle H. Lelong, J Zhang et al. · Proceedings of the National Academy of Sciences · 1992 · 397 citations